How Does Eli Lilly Stock Stack Up Against Its Peers?
Eli Lilly’s stock has underperformed some key peers over the past year, yet its significant growth in areas like GLP-1 therapies remains notable. A closer look reveals superior profitability and robust revenue acceleration, fueled by its strong pipeline and market leadership in key therapeutic areas. However, a premium valuation and lower free cash flow generation suggest high growth expectations and substantial investment in future drivers, balanced against intensifying competitive and pricing pressures within the pharmaceutical sector.
- LLY’s 45.6% operating margin, highest among peers, reflects robust GLP-1 drug demand, enabling strong pricing power and an efficient product mix.
- LLY’s 44.7% revenue growth, outpacing peers, stems from surging GLP-1 drug sales (Mounjaro, Zepbound) driving dominance in diabetes/obesity markets.
- LLY’s 16.8% stock gain and 43.8 PE, while peers delivered more, signals investors’ high future growth expectations for its blockbuster GLP-1 pipeline.
Here’s how Eli Lilly stacks up across size, valuation, and profitability versus key peers.
| LLY | JNJ | MRK | PFE | ABBV | AMGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 903.3 | 584.1 | 290.5 | 152.4 | 402.4 | 202.8 |
| Revenue ($ Bil) | 65.2 | 94.2 | 65.0 | 62.6 | 61.2 | 36.8 |
| PE Ratio | 43.8 | 21.8 | 15.9 | 19.6 | 95.2 | 26.3 |
| LTM Revenue Growth | 44.7% | 6.0% | 1.3% | -1.6% | 8.6% | 10.0% |
| LTM Operating Margin | 45.6% | 27.2% | 34.0% | 27.8% | 32.8% | 24.7% |
| LTM FCF Margin | 9.2% | 20.5% | 19.0% | 14.5% | 29.1% | 22.0% |
| 12M Market Return | 16.8% | 49.6% | 28.4% | 7.6% | 9.7% | 19.7% |
For more details on Eli Lilly, read Buy or Sell LLY Stock. Below we compare LLY’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Will Musk’s $1.6 Trillion Disruption Be His Biggest Yet?
- Rocket Lab’s $35 Billion Valuation Makes Little Sense – Until You Look at 2035
- Does Alphabet Stock Still Have Room to Run?
- How Advanced Micro Devices Stock Gained 90%
- How To Earn 13% Yield While Waiting to Buy APH 30% Cheaper
- Cash Machine Trading Cheap – Adobe Stock Set to Run?
| LTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| LLY | 44.7% | 44.7% | 32.0% | 19.6% |
| JNJ | 6.0% | 6.0% | 4.3% | 6.5% |
| MRK | 1.3% | 1.3% | 6.7% | 1.4% |
| PFE | -1.6% | -1.6% | 6.8% | -41.1% |
| ABBV | 8.6% | 8.6% | 3.7% | -6.4% |
| AMGN | 10.0% | 10.0% | 18.6% | 7.1% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| LLY | 45.6% | 45.6% | 37.8% | 30.3% |
| JNJ | 27.2% | 27.2% | 23.9% | 25.8% |
| MRK | 34.0% | 34.0% | 31.5% | 4.9% |
| PFE | 27.8% | 27.8% | 23.5% | 7.4% |
| ABBV | 32.8% | 32.8% | 21.1% | 24.9% |
| AMGN | 24.7% | 24.7% | 21.7% | 28.0% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| LLY | 43.8 | 46.7 | 65.7 | 100.1 |
| JNJ | 21.8 | 18.6 | 24.8 | 11.3 |
| MRK | 15.9 | 14.4 | 14.7 | 757.8 |
| PFE | 19.6 | 18.2 | 18.7 | 76.7 |
| ABBV | 95.2 | 95.6 | 73.5 | 56.3 |
| AMGN | 26.3 | 22.8 | 34.2 | 22.9 |
Still not sure about LLY stock? Consider portfolio approach.
The Right Way To Invest Is Through Portfolios
Single stocks swing wildly but staying invested matters. A well built portfolio helps you stay invested, captures upside and softens the blows from individual stocks.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.